Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A.P.L. vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
92% bound primarily to albumin
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
0.4 L/kg, indicating distribution primarily in extracellular fluid
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
Oral: 85% with high first-pass effect; IM: 100%
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not approved for pediatric use.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
No black box warning.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No known food interactions. Avoid alcohol during treatment.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A.P.L. vs ANTAGONATE, answered by our medical review team.
A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A.P.L. and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A.P.L. and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.